Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy

Antibody therapy targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA4) elicited survival benefits in cancer patients; however, the overall response rate is limited. In addition, anti-CTLA4 antibody therapy induces a high rate of immune-related adverse events. The underlying factors that may...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingyu, Liu, Dai, Li, Guangfu, Staveley-O’Carroll, Kevin F., Graff, Julie N., Li, Zihai, Wu, Jennifer D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435412/
https://www.ncbi.nlm.nih.gov/pubmed/28560327
http://dx.doi.org/10.1126/sciadv.1602133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435412/
https://www.ncbi.nlm.nih.gov/pubmed/28560327
http://dx.doi.org/10.1126/sciadv.1602133

Ejemplares similares